Sugi Predict

Sugi Predict / Targets / PROKR1

PROKR1

Prokineticin receptor 1 · Q8TCW9 · PROKR1 on Sugi Atlas →

19,636 patent compounds predicted against PROKR1, 5,930 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL326251 SCHEMBL326251 1.00 20/20
SCHEMBL326896 SCHEMBL326896 0.81 20/20
SCHEMBL1752180 SCHEMBL1752180 0.77 20/20
SCHEMBL1750900 SCHEMBL1750900 0.74 20/20
SCHEMBL326177 SCHEMBL326177 0.72 20/20
SCHEMBL1752541 SCHEMBL1752541 0.72 20/20
SCHEMBL2034423 SCHEMBL2034423 0.68 20/20
SCHEMBL1751296 SCHEMBL1751296 0.66 20/20
SCHEMBL1752539 SCHEMBL1752539 0.65 20/20
SCHEMBL2031947 SCHEMBL2031947 0.63 20/20
SCHEMBL1752011 SCHEMBL1752011 0.61 20/20
SCHEMBL325491 SCHEMBL325491 0.76 19/20
SCHEMBL325624 SCHEMBL325624 0.63 19/20
SCHEMBL2027078 SCHEMBL2027078 0.62 19/20
SCHEMBL1752302 SCHEMBL1752302 0.61 19/20
SCHEMBL325234 SCHEMBL325234 0.59 19/20
SCHEMBL326396 SCHEMBL326396 0.50 19/20
SCHEMBL326449 SCHEMBL326449 0.82 18/20
SCHEMBL1751295 SCHEMBL1751295 0.60 18/20
SCHEMBL1750898 SCHEMBL1750898 0.59 18/20

Clinical trials — most relevant to PROKR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Medication, Weight Gain and GI Hormones PHASE4COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell. PHASE4UNKNOWN
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity PHASE3COMPLETED
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age PHASE3RECRUITING
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes PHASE2RECRUITING
The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans PHASE2NOT_YET_RECRUITING
The Role of Islet GLP-1 in the Pathogenesis of Prediabetes PHASE2RECRUITING
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity PHASE2COMPLETED
Secretin in Ex-situ Liver Perfusion PHASE1/PHASE2ENROLLING_BY_INVITATION
Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
The Role of Phosphodiesterase Inhibitors in Incretin Secretion PHASE1COMPLETED
Effect of GSK962040 on Oesophageal Function PHASE1COMPLETED
Magnetic Resonance Imaging of Motility in Crohn's 2 nanCOMPLETED
Role of the Microbiota in Obesity: Effect After Bariatric Surgery nanCOMPLETED
Magnetic Resonance Imaging of Motility in Crohn's 1 nanCOMPLETED
Study of the Molecular Basis in the Pathophysiology of Food Intake and Growth in Children nanCOMPLETED
Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology nanCOMPLETED
Endoscopic Gastric Reduction of Gastric Mucosa in Obesity nanUNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Pre- and Post-prandial Levels of Appetite Regulatory Hormones in Adults nanCOMPLETED
The PRO-SOma COla (PROSOCO) Study nanUNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN
Nutritional Management of Acute and Chronic Enterocutaneous Fistulae nanUNKNOWN
Dietary Carbohydrate and GERD in Veterans nanCOMPLETED
The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function nanCOMPLETED
The Lean Living Study nanCOMPLETED
Calorie Restriction in Multiple Sclerosis nanACTIVE_NOT_RECRUITING
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood. nanUNKNOWN
Eating Behaviour in Crohn's Disease nanCOMPLETED
Facilitated Release of Endogenous Enterokines nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PROKR1 binder may also engage these)

ProteinNameSimilarity
PROKR2 Prokineticin receptor 2 1.000 landscape →
Q8SPN2 — 1.000 Q8SPN2 →
Q8SPN1 — 1.000 Q8SPN1 →
Q8K458 — 1.000 Q8K458 →
Q9JKL1 — 1.000 Q9JKL1 →
Q8R416 — 0.999 Q8R416 →
Q8R415 — 0.999 Q8R415 →
O62809 — 0.979 O62809 →
Q924H0 — 0.979 Q924H0 →
Q9EQD2 — 0.979 Q9EQD2 →
P58308 — 0.977 P58308 →
P90745 — 0.974 P90745 →
Q9DDN6 — 0.973 Q9DDN6 →
NPY2R Neuropeptide Y receptor type 2 0.972 landscape →
P97295 — 0.972 P97295 →
Q9Z2D5 — 0.972 Q9Z2D5 →
Q9Y5Y3 — 0.971 Q9Y5Y3 →
HCRTR2 Orexin receptor type 2 0.971 landscape →
Q9GK74 — 0.971 Q9GK74 →
P35371 — 0.971 P35371 →
Q18179 — 0.970 Q18179 →
P79945 — 0.970 P79945 →
O54798 — 0.970 O54798 →
P56719 — 0.970 P56719 →
Q18534 — 0.970 Q18534 →
Q5IS62 — 0.970 Q5IS62 →
Q9TUP7 — 0.969 Q9TUP7 →
P79113 — 0.969 P79113 →
Q6VZZ7 — 0.969 Q6VZZ7 →
Q8K418 — 0.969 Q8K418 →